Sivik Global Healthcare LLC Increases Stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Sivik Global Healthcare LLC boosted its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 10.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 55,000 shares of the biotechnology company’s stock after purchasing an additional 5,000 shares during the period. BioMarin Pharmaceutical makes up about 2.2% of Sivik Global Healthcare LLC’s portfolio, making the stock its 25th biggest position. Sivik Global Healthcare LLC’s holdings in BioMarin Pharmaceutical were worth $5,303,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of BMRN. KB Financial Partners LLC increased its holdings in shares of BioMarin Pharmaceutical by 51.3% in the third quarter. KB Financial Partners LLC now owns 348 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 118 shares during the period. Castleview Partners LLC acquired a new stake in BioMarin Pharmaceutical during the 3rd quarter valued at approximately $35,000. Lindbrook Capital LLC boosted its holdings in shares of BioMarin Pharmaceutical by 259.8% in the 4th quarter. Lindbrook Capital LLC now owns 385 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 278 shares during the last quarter. Allworth Financial LP grew its position in BioMarin Pharmaceutical by 54.9% during the 4th quarter. Allworth Financial LP now owns 604 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 214 shares during the period. Finally, Signaturefd LLC raised its stake in shares of BioMarin Pharmaceutical by 17.9% during the 3rd quarter. Signaturefd LLC now owns 1,283 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 195 shares during the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on BMRN. Wells Fargo & Company raised their price objective on shares of BioMarin Pharmaceutical from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, April 25th. Robert W. Baird reduced their price target on BioMarin Pharmaceutical from $127.00 to $104.00 and set an “outperform” rating for the company in a report on Tuesday, January 30th. Scotiabank raised their price objective on BioMarin Pharmaceutical from $83.00 to $85.00 and gave the company a “sector perform” rating in a report on Thursday, April 25th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $100.00 target price on shares of BioMarin Pharmaceutical in a research note on Friday, February 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $110.00 price target on shares of BioMarin Pharmaceutical in a report on Thursday, April 25th. Seven analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $107.50.

BioMarin Pharmaceutical Trading Down 1.7 %

BioMarin Pharmaceutical stock traded down $1.37 during trading on Tuesday, reaching $80.76. 2,018,244 shares of the company were exchanged, compared to its average volume of 1,460,833. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.51 and a quick ratio of 1.57. The stock’s 50 day simple moving average is $87.29 and its two-hundred day simple moving average is $89.07. The company has a market capitalization of $15.24 billion, a P/E ratio of 75.48, a PEG ratio of 1.36 and a beta of 0.31. BioMarin Pharmaceutical Inc. has a 52-week low of $76.02 and a 52-week high of $99.56.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings results on Thursday, February 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.05. BioMarin Pharmaceutical had a net margin of 8.31% and a return on equity of 5.39%. The firm had revenue of $646.21 million for the quarter, compared to analysts’ expectations of $639.53 million. During the same quarter in the previous year, the company posted $0.11 EPS. The company’s revenue was up 20.2% compared to the same quarter last year. On average, equities research analysts expect that BioMarin Pharmaceutical Inc. will post 1.85 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Jeffrey Robert Ajer sold 4,000 shares of the stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $87.07, for a total value of $348,280.00. Following the completion of the transaction, the executive vice president now directly owns 94,047 shares in the company, valued at $8,188,672.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, EVP Jeffrey Robert Ajer sold 4,000 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $87.07, for a total transaction of $348,280.00. Following the completion of the transaction, the executive vice president now owns 94,047 shares of the company’s stock, valued at approximately $8,188,672.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jean Jacques Bienaime sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $88.28, for a total value of $1,324,200.00. Following the completion of the sale, the director now directly owns 419,602 shares in the company, valued at approximately $37,042,464.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 103,229 shares of company stock valued at $9,062,967. 1.85% of the stock is currently owned by company insiders.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.